IOL Chemicals and Pharmaceuticals Ltd
NSE:IOLCP
Intrinsic Value
IOL Chemicals & Pharmaceuticals Ltd. engages in the manufacture of organic and inorganic chemical compounds. [ Read More ]
The intrinsic value of one
IOLCP
stock under the Base Case scenario is
599.37
INR.
Compared to the current market price of 368.1 INR,
IOL Chemicals and Pharmaceuticals Ltd
is
Undervalued by 39%.
IOL Chemicals and Pharmaceuticals Ltd's market capitalization is 21.6B INR.
IOLCP stock price is 368.1 INR.
IOLCP stock price (368.1 INR) is 39% less than its Intrinsic Value (599.37 INR).
IOLCP stock price (368.1 INR) is 48% less than its Relative Value (705.03 INR). Open Relative Valuation
IOLCP has upside potential of 39% compared to the average analyst price target.
Open Wall St Estimates
IOLCP's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 10%.
IOLCP's Revenue has grown by 1% over the past 12 months.
IOLCP's ROE (Return on Equity) for the past 12 months is positive and is equal to 11%.
IOLCP has positive Net Income for the last twelve months.
IOLCP has positive Free Cash Flow for the last twelve months.
IOLCP's Revenue has been growing by 4% per year for the last 3 years.
IOLCP has positive Operating Income for the last twelve months.
IOLCP's Revenue is forecast to grow at a rate of 9% per year over the next 3 years.
IOLCP has negative Net Debt. This means that the company has more cash and short-term investments (758m INR) than debt (591m INR).
IOLCP has positive three-year average ROE (Return on Equity): 20%. The company is efficient at transforming stockholders' equity into net income.
IOLCP has positive three-year average ROIC (Return on Invested Capital): 20%. The company is efficient at using invested capital to generate operating income.
IOLCP has positive Gross Profit for the last twelve months.
IOLCP's ROE (Return on Equity) has significantly decreased in the last 3 years from 43% to 11%.
IOLCP's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 48% to 10%.
IOLCP earns more than enough operating income (2B INR) to safely cover interest payments on its debt (179m INR).
IOLCP's short-term assets (9B INR) exceed its short-term liabilties (4B INR).
IOLCP's D/E (Debt to Equity) is very low and is equal to 0.04.
IOLCP's long-term assets (21B INR) exceed its long-term liabilties (5B INR).
IOLCP's Altman Z-Score is very high and is equal to 6.03.
Valuation Backtest
IOL Chemicals and Pharmaceuticals Ltd
Run backtest to discover the historical profit from buying and selling
IOLCP
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
This note will be permanently deleted.
IOL Chemicals and Pharmaceuticals Ltd
Balance Sheet Decomposition
IOL Chemicals and Pharmaceuticals Ltd
| Current Assets | 9.2B |
| Cash & Short-Term Investments | 758.1m |
| Receivables | 5B |
| Other Current Assets | 3.5B |
| Non-Current Assets | 11.6B |
| Long-Term Investments | 2.4B |
| PP&E | 8.8B |
| Intangibles | 111.8m |
| Other Non-Current Assets | 293.9m |
| Current Liabilities | 4.3B |
| Accounts Payable | 3.1B |
| Short-Term Debt | 590.5m |
| Other Current Liabilities | 566.8m |
| Non-Current Liabilities | 615.3m |
| Other Non-Current Liabilities | 615.3m |
Earnings Waterfall
IOL Chemicals and Pharmaceuticals Ltd
|
Revenue
|
22.2B
INR
|
|
Cost of Revenue
|
-14.5B
INR
|
|
Gross Profit
|
7.6B
INR
|
|
Operating Expenses
|
-5.5B
INR
|
|
Operating Income
|
2.2B
INR
|
|
Other Expenses
|
-461.9m
INR
|
|
Net Income
|
1.7B
INR
|
Free Cash Flow Analysis
IOL Chemicals and Pharmaceuticals Ltd
| INR | |
| Free Cash Flow | INR |
IOLCP Profitability Score
Profitability Due Diligence
IOL Chemicals and Pharmaceuticals Ltd's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
IOL Chemicals and Pharmaceuticals Ltd's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
IOLCP Solvency Score
Solvency Due Diligence
IOL Chemicals and Pharmaceuticals Ltd's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Score
IOL Chemicals and Pharmaceuticals Ltd's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IOLCP Price Targets Summary
IOL Chemicals and Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
IOLCP
is 511.53 INR
with a low forecast of 497.93 INR and a high forecast of 535.5 INR.
Shareholder Return
IOLCP Price
IOL Chemicals and Pharmaceuticals Ltd
| Average Annual Return | 66.46% |
| Standard Deviation of Annual Returns | 187.91% |
| Max Drawdown | -67% |
| Market Capitalization | 21.6B INR |
| Shares Outstanding | 58 705 500 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
IOL Chemicals and Pharmaceuticals Ltd
Country
Industry
Market Cap
Dividend Yield
Description
IOL Chemicals & Pharmaceuticals Ltd. engages in the manufacture of organic and inorganic chemical compounds. The company is headquartered in Ludhiana, Punjab and currently employs 2,316 full-time employees. The company went IPO on 2010-11-05. The firm is engaged in manufacturing and selling of organic chemicals, specialty, intermediates, and bulk drugs. Its product portfolio covers various therapeutic categories, such as Pain Management, Anti-diabetic, Anti-hypertensive, and Anti-convulsant, amongst others. Its active pharma ingredients (API) product portfolio include Ibuprofen, Ibuprofen Lysinate, Ibuprofen Sodium, Dex-Ibuprofen, Metformin HCL, Clopidogrel Bisulphate (Form II), Pantoprazole Sodium, Fenofibrate, Gabapentin, Lamotrigine, Ursodeoxycholic Acid, Losartan Potassium and Levetiracetam. Its specialty chemical division include Ethyl Acetate, Iso Butyl Benzene, Acetyl Chloride and Mono Chloro Acetic Acid. The firm caters to the pharmaceutical and specialty chemical requirements across both domestic and international markets. The company serves Austria, Belgium, Hungry, Spain, Germany, Italy, Netherlands, Switzerland and others.
Contact
IPO
Employees
Officers
The intrinsic value of one
IOLCP
stock under the Base Case scenario is
599.37
INR.
Compared to the current market price of 368.1 INR,
IOL Chemicals and Pharmaceuticals Ltd
is
Undervalued by 39%.
You don't have any saved screeners yet
